Effect of the Infusion of OKY-046, a Thromboxane A2 Synthase Inhibitor, on Urinary Metabolites of Prostacyclin and Thromboxane A2 in Healthy Human Subjects

H Morio; A Hirai; T Terano; Y Tamura; S Yoshida

doi:10.1055/s-0038-1651595

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1993; 69(03): 276-281
DOI: 10.1055/s-0038-1651595

Original Article

Platelets

Schattauer GmbH Stuttgart

Effect of the Infusion of OKY-046, a Thromboxane A₂ Synthase Inhibitor, on Urinary Metabolites of Prostacyclin and Thromboxane A₂ in Healthy Human Subjects

H Morio

The Second Department of Internal Medicine, Chiba University Medical School, Chiba, Japan

,

A Hirai

The Second Department of Internal Medicine, Chiba University Medical School, Chiba, Japan

,

T Terano

The Second Department of Internal Medicine, Chiba University Medical School, Chiba, Japan

,

Y Tamura

The Second Department of Internal Medicine, Chiba University Medical School, Chiba, Japan

,

S Yoshida

The Second Department of Internal Medicine, Chiba University Medical School, Chiba, Japan

› Institutsangaben

Abstract

als PDF herunterladen

Summary

The influence of OKY-046, a selective thromboxane synthase inhibitor, on prostanoid formation in healthy human subjects was studied. Vehicle (5% glucose solution) or OKY-046 in 5% glucose solution at 15 μg kg⁻¹ min⁻¹ was intravenously administered to five male healthy volunteers for 6 h. Platelet aggregation and thromboxane B₂ (TXB₂) formation induced by collagen and arachidonic acid were suppressed by the infusion of OKY-046, while both were not affected by the infusion of vehicle. Urinary excretion of 11-dehydro-thromboxane B₂, one of major urinary metabolites of thromboxane A₂ (TXA₂) was decreased by the infusion of OKY-046, while that of 2,3-dinor-6-keto-prostaglandin F_1α, one of major urinary metabolites of prostacyclin (PGI₂) was increased. The present study demonstrated that the infusion of OKY-046 improved the balance of TXA₂/PGI₂ into antithrombotic state in healthy subjects. It was also suggested that endogenously produced (probably platelet-derived) endoperoxides could be redirected into prostacyclin in vivo.

PDF (1484 kb)

Referenzen

References
1 Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998
2 Antiplatelet trialists’ collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-331
3 Steering committee of physicians’ health study research group. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 321: 129-135
4 Verheugt FWA, Laarse AVD, Fünke-Kupper AJ, Sterkman LGW, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990; 66: 267-270
5 Needleman P, Raz A, Ferrendelli JA, Minkes M. Application of imidazole as a selective inhibitor of thromboxane synthetase in human platelets. Proc Natl Acad Sci USA 1977; 74: 1716-1720
6 Moncada S, Buting S, Mullane K, Thorogood P, Vane JR, Raz A, Needleman P. Imidazole: A selective inhibitor of thromboxane synthetase. Prostaglandins 1977; 13: 611-618
7 Smith JB. Pharmacology of thromboxane synthetase inhibitors. Fed Proc 1987; 46: 139-143
8 Korbut R, Dembiñska-Kiec A, Swies J, Zmuda A, Gryglewski RJ. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors. Thromb Haemostas 1987; 58: 827-830
9 Vermylen J, Defreyn G, Carreras LO, Machin SJ, Sehaeren JV, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet 1981; 1: 1073-1075
10 Marcus AJ, Weksler BB, Jaffe EA, Broekman JM. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66: 979-986
11 Schafer AI, Crawford DD, Gimbrone MAJ. Unidirectional transfer of prostaglandin endoperoxides between platelets and endothelial cells. J Clin Invest 1984; 73: 1105-1124
12 FitzGerald GA, Oates JA. Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 1984; 35: 633-640
13 Reilly IAG, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 1987; 69: 180-186
14 Fischer S, Struppler M, Bohlig B, Bernutz C, Weber W, Weber PC. The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man. Circulation 1983; 68: 821-826
15 Henriksson P, Rasmanis G, Edhag O, Vesteqvist O, Gréen K. Thromboxane synthase inhibition: “endoperoxide shunt phenomenon” does not occur in healthy humans in vivo. Prostaglandins 1990; 39: 99-107
16 FitzGerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into circulation of normal man. J Clin Invest 1981; 68: 1272-1276
17 Rosenkranz B, Fischer C, Weimer K, Frölich J. Metabolism of prostacyclin and 6-keto-prostaglandin F_1α in man. J Biol Chem 1980; 255: 10194-10198
18 Wennmalm A, FitzGerald GA. Excretion of prostacyclin and thromboxane A₂ metabolites during leg exercise in humans. Am J Physiol 1988; 255: H15-H18
19 Vesterqvist O, Gréen K. Development of a GC-MS method for quantitation of 2,3-dinor-6-keto-PGF_1α and determination of the urinary excretion rates in healthy humans under normal conditions and following drugs. Prostaglandins 1984; 28: 139-154
20 Vesterqvist O, Gréen K. Urinary excretion of 2,3-dinor-thromboxane B₂ in man under normal conditions, following drugs and during some pathological conditions. Prostaglandins 1984; 27: 627-644
21 Garcia-Szabo R, Kern DF, Malik AB. Pulmonary vascular response to thrombin: Effects of thromboxane synthetase inhibition with OKY-046 and OKY-1581. Prostaglandins 1984; 28: 851-866
22 Hirafuji M, Ogura Y. Endogenous biosynthesis of prostaglandin I₂ and thromboxane A₂ by isolated rat dental pulp. Biochem Pharmacol 1983; 32: 2983-2985
23 Kubo K, Kobayashi T, Handa K, Kusama S, Sakai A, Ueda G. Effects of OKY-046 on endotoxin-induced lung injury in conscious sheep. Am Rev Resp Dis 1983; 127: 303
24 Westlund P, Kumlin M, Nordenström A, Granström E. Circulating and urinary thromboxane B₂ metabolites in the rabbit: 11-dehydrothromboxane B₂ as parameter of thromboxane production. Prostaglandins 1986; 31: 413-443
25 Westlund P, Granström E, Kumlin M, Nordenström A. Identification of 11-dehydro-TXB₂ as a suitable parameter for monitoring thromboxane production in the human. Prostaglandins 1986; 31: 929-960
26 Balazy M, Brass EP, Gerber JG, Nies AS. Facile method for preparation of 2,3-dinor-6-keto-PGF_1α. The major urinary metabolite of prostacyclin. Prostaglandins 1988; 36: 421-430
27 Lawson JA, Patrono C, Ciabattoni G, FitzGerald GA. Long-lived enzymatic metabolites of thromboxane B₂ in human circulation. Anal Biochem 1986; 155: 198-205
28 Fukushima M, Kubo K, Yoshimura K, Shibamoto T, Fujimoto K, Hirai K, Kobayashi T, Kusama S, Komatsu H, Hamano S, Ujiie A, Shimizu M, Miyagi M, Morita K, Mikoshiba I, Hiraku S, Ohki S. Phase I study of OKY-046, a selective thromboxane inhibitor; Study on one-shot and continuous intravenous administration. Yakuri-to-Chiryo 1986; 14: 277-307
29 Otomo E, Ktsuzawa T, Kogure K, Hirai S, Goto F, Terashi A, Tazaki Y, Araki G, Ito E, Fujishima M, Nakashima M. Clinical usefulness of OKY-046 on the acute stage of cerebral thrombosis. Double blind trial in comparison with placebo. Rinsho-Iyaku 1991; 7: 353-388
30 Takenaga M, Kitagawa H, Hirai A, Tamura Y, Yoshida S. Mechanism of anti-platelet aggregating action of dilazep. J Pharmacobio-Dyn 1985; 8: 77-83
31 Lands WEM, Culp BR, Hirai A, Gorman R. Relationship of thromboxane generation to the aggregation of platelet from humans: Effects of eicosapentaenoic acid. Prostaglandins 1985; 30: 819-825
32 Powell WS. Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilylsilica. Prostaglandins 1980; 20: 947-957
33 Kumlin M, Granström E. Radioimmunoassay for 11-dehydro-TXB₂: A method for monitoring thromboxane production in vivo. Prostaglandins 1986; 32: 741-767
34 Chiabrando C, Pinciroli V, Campoleoni A. Quantitative profiling of 6-ketoprostaglandin F_1α, 2,3-dinor-6-ketoprostaglandin F_1α, thromboxane B₂ and 2,3-dinor-thromboxane B₂ in human and rat urine by immunoaffinity extraction with gas chromatography-mass spectrometry. J Chromatogr 1989; 495: 1-11
35 Nakagawa A, Kobayashi N, Haruyama H, Takayama T, Muramatsu S, Nakamura K. Studies on the determination of 2,3-dinor-6-keto-PGF_1α by GC-MS. Proc Jpn Soc Biomed Mass Spectrum 1990; 15: 123-128
36 Tallarida RJ, Murray RB. Manual of Pharmacologic Calculation with Computer Programs. 2.. New York: Springer; 1986
37 Casas J, Rosello J, Gelpi E. Determination of 2,3-dinor-6-ketopros-taglandin F_1α in urine samples by liquid chromatography and radioimmunoassay. J Chromatogr 1986; 383: 317-324
38 Ciabattoni G, Boss AH, Daffonchio L, Daugherty J, FitzGerald GA, Catella F, Dray F, Patrono C. Radioimmunoassay measurement of 2.3-dinor metabolites of prostacyclin and thromboxane in human urine. Adv Prostaglandin Thromboxane Leukotriene Res 1987; 17: 598-602
39 Lellouche F, Fradin A, FitzGerald G, Maclouf J. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A₂ and prostacyclin. Prostaglandins 1990; 40: 297-310
40 Hoet B, Arnout J, Geet CV, Deckmyn H, Verhaeghe R, Vermylen J. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma β-thromboglobulin levels in patients with documented peripheral arterial disease. Thromb Haemostas 1990; 64: 87-90